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OBJECTIVE
To evaluate the length of time required for atheros-
clerotic plaque stabilization in acute coronary syndromes 
(ACS), using inﬂ  ammatory markers. 
METHODS 
In this prospective study, C-reactive protein (CRP), 
ﬁ  brinogen, factor VIIIc, interleukin-6 (IL-6), and tumor 
necrosis factor-α (TNF-α) levels were  measured  on 
admission, at discharge, and three and six months post-
discharge in 40 patients with non-ST-segment elevation 
ACS (NSTE-ACS) and 40 healthy subjects. 
RESULTS 
C-reactive protein levels were signiﬁ  cantly higher on 
admission and at discharge, but not at three and six 
months post-discharge, compared with the control group. 
Fibrinogen levels remained unchanged, except at six 
months, when they were signiﬁ  cantly lower than in the 
control group. Factor VIII-c did not differ from that of the 
control group on admission, but it was signiﬁ  cantly higher 
at discharge, with no differences at three and six months. 
Interleukin-6 levels were signiﬁ  cantly higher than in the 
control group in all time points. However, they declined 
signiﬁ  cantly between discharge and three months. In no 
time point was TNF-α signiﬁ  cantly different from that of 
the control group. Only IL-6 correlated signiﬁ  cantly and 
independently with future cardiovascular events.
CONCLUSIONS 
With respect to CRP and factor VIIIc, plaque stabili-
zation is suggested in up to three months; IL-6 analysis 
suggests stabilization as from the third month, although 
it remained higher than that of the control group for up to 
six months. Only IL-6 showed prognostic value for further 
events within a year. 
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Acute coronary syndromes (ACS) – unstable angina 
and myocardial infarction – are caused mainly by rupture 
or erosion of atherosclerotic plaque, with subsequent 
thrombus formation. It is known that plaque instability, 
among other characteristics, is closely related to the 
inﬂ  ammatory process1-4.
Of the circulating inﬂ  ammatory markers, C-reactive 
protein (CRP) is the most extensively studied; high 
CRP plasma levels are found in ACS patients and are 
associated with increased rates of future events5. On 
the other hand, interleukin-6, which prompts C-reactive 
protein production, is also elevated in ACS patients and 
is associated with worse prognosis, thereby reinforcing 
the role of inﬂ   ammation in these syndromes6. Tumor 
necrosis factor-α (TNF-α), a cytokine produced mostly by 
activated macrophages, stimulates the synthesis of other 
cytokines7. Persistently increased TNF-α levels after acute 
myocardial infarction (AMI) are correlated with worse 
prognosis; however, little information is available on TNF-
α kinetics in non-ST-segment elevation ACS8. Fibrinogen is 
an acute-phase protein directly involved in the coagulation 
cascade; increased ﬁ  brinogen levels are associated with 
higher risk of thrombotic events9 and higher risk of events 
in ACS patients10-14. Finally, factor VIII-c, a procoagulant 
enzyme cofactor, is also involved in inﬂ  amation15 and is 
a marker of ischemic heart disease16-18.
Little has been published about how long it takes 
for stabilized coronary lesions to heal completely in 
patients with non-ST-segment elevation ACS. A study 
using cell adhesion molecules (CAMs) suggested that the 
inﬂ  ammatory response might persist for up to six months 
following an acute coronary event19.
The primary focus of this study was to evaluate 
the length of time required for atherosclerotic plaque 
to become stabilized in patients with non-ST-segment 
elevation ACS treated clinically, through the behavior of 
plasma inﬂ  ammatory and coagulation markers levels.
METHODS 
Forty out of the 64 patients admitted to our hospital 
between September 2000 and May 2001 with unstable 
angina and no-ST-segment elevation AMI were included 
in the study (22 men; mean age 61 ± 12). Forty age- 
and sex-matched healthy volunteers served as the control 
group. Patients were followed-up over one year. 
Inclusion criteria were chest pain lasting 24 hours, 
suggestive of myocardial ischemia of accelerated 
pattern, or a prolonged one (> 20 minutes), or with 
recurrent episodes at rest, or at minimal exertion, in 
addition to at least one of the following: (a) new or 
presumed new ECG changes (any of the following three 
characteristics): ST-segment depression ≥ 0.5 mm, 
transient ST-segment elevation (< 20 minutes) ≥ 1 mm, 
T-wave inversion ≥ 3 mm in two or more contiguous 
leads; (b) and raised levels of cardiac markers (CKMB 
≥ 2X the upper limit of normal). 
Exclusion criteria were persistent ST-segment elevation; 
secondary angina; history of percutaneous coronary 
intervention (PCI) or coronary artery bypass grafting 
(CABG) within the previous six months; left bundle branch 
block (LBBB) or pacemaker rhythm; ﬁ  brinolytic therapy in 
the last 48 hours; any inﬂ  ammation, infection or neoplasic 
disease; regular or chronic use of anti-inﬂ  ammatory drugs 
in the previous two months; AMI and stroke within the 
past six months; severe congestive heart failure (CHF) 
or cardiogenic shock; severe systemic disease; serum 
creatinine > 2.5 mg/dL; or surgery or trauma within the 
past thirty days. Patients who underwent CABG or PCI 
during the study were also excluded (nine patients were 
excluded on the basis of this criterion).
Clinical management - In-hospital medications were 
used according to the medical approach (see Table 1). 
The assistant doctor also made decisions regarding 
invasive or conservative strategy and the need of coronary 
revascularization.
Blood samples - Peripheral venous blood samples were 
collected on admission, at hospital discharge, and three 
and six months after discharge. A single measurement 
was performed in healthy controls. All samples (patients 
and controls) were centrifuged, stored at -70 °C, and 
tested for high-sensitivity CRP , IL-6, TNF-α, ﬁ  brinogen and 
factor VIII-c in a single series at the end of the study. 
Laboratory assessment - High-sensitivity CRP (hs-CRP) 
was determined by particle-enhanced immunoturbidimetric 
assay (COBAS INTEGRA 700; Roche Diagnostics). IL-6 
and TNF-α were evaluated by ELISA (Enzyme-Linked 
Immunosorbent Assay- R&D Systems). Fibrinogen was 
measured using the automated Clauss method (Fibriquik, 
manufactured by Organon Teknika). Factor VIII activity 
was measured by determining the ability of the tested 
sample to correct the clotting time of factor VIII-deﬁ  cient 
plasma (Organon Teknika).
Purpose - The primary purpose of this study was 
to indirectly evaluate the length of time required for 
atherosclerotic plaque stabilization in ACS patients 
(unstable angina and non-ST-segment elevation AMI), 
by measuring inﬂ   ammatory markers (CRP , ﬁ   brinogen, 
factor VIII, IL-6, and TNF-α) during six months after 
hospital discharge. The secondary purpose was to 
correlate the plasma concentrations of these markers 
with the prognosis (risk of future cardiovascular events) 
in patients with non-ST-segment elevation ACS in up to 
one year of follow-up. 
Statistical analysis - The sample size of forty patients 
was based on probabilistic properties of means and 
proportions estimators, because no a priori information 
is available for an estimation that takes into account the 
accuracy of ﬁ  nal results. As the majority of inﬂ  ammatory 
marker values were not normally distributed, data were 
expressed as median (25th-75th percentile); when there 
was a normal distribution, values were expressed as mean 
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± standard deviation. 
To compare both groups, the Mann-Whitney test 
(non-parametric) was used for non-normally distributed 
values, while Student’s unpaired t-test, Welch-corrected, 
was used for normally distributed values. 
Categorical variables were expressed as number and 
percentage. Fisher’s exact test was performed to compare 
these variables. 
When the patient was his own control and thus acted 
as paired groups do, Wilcoxon’s non-parametric paired 
test was used to compare the different time points 
analyzed. The same comparisons in the different time 
points were performed for normally-distributed markers 
using the paired t-test.
Correlation between cytokines and acute phase 
protein values was performed using a Spearman non-
parametric correlation. 
Every marker was compared with the composite 
endpoint of recurrent angina, readmission for angina, 
reinfarction or cardiovascular death after a one-year 
follow-up. In these analyses, the Mann-Whitney test 
(univariate analysis) and logistic regression (multivariate 
analysis) were used.
Group differences were considered statistically 
signiﬁ  cant when p ≤ 0.05 (two-tailed).
Ethical considerations - The project was approved 
by the Institutional Research Ethics Committee of the 
Faculdade de Medicina de São José do Rio Preto, São 
Paulo (Famerp) and the Faculdade de Medicina da 
Universidade de São Paulo (FMUSP). Informed consent 
was obtained from all patients.
RESULTS
The characteristics of the study population are shown 
in Table 1. As may be noted, groups were paired according 
to age and gender. As expected, the case group showed 
a larger proportion of patients with speciﬁ  c risk factors 
and pre-treatments.
Figure 1 shows that median CRP levels were signiﬁ  -
cantly higher in ACS patients, compared to control 
subjects, both on admission and at discharge, but not 
at three and six months. Median IL-6 levels declined 
significantly between discharge and three months. 
However, they remained signiﬁ  cantly higher than those 
of the control group for up to six months (Fig. 2). Median 
TNF-α levels decreased signiﬁ  cantly between three and 
six months after discharge. Yet, the levels compared 
with the controls did not reach statistical signiﬁ  cance at 
any time of follow-up (Fig. 3). Change in patterns over 
time were also found for ﬁ  brinogen (Fig. 4), although no 
signiﬁ  cant increase was found during follow-up compared 
with controls. Factor VIII-c levels were signiﬁ  cantly higher 
at discharge, compared with controls, but not at three 
and six months (Fig. 5).
Correlations between acute-phase proteins and 
cytokines- There were signiﬁ  cant correlations between 
CRP and IL-6 levels measured on admission (r = 0.5; 
p < 0.001), at discharge (r = 0.6; p < 0.001), and 
after three months (r = 0.4; p < 0.007); between 
CRP and ﬁ  brinogen levels measured on admission (r 
= 0.4; p = 0.003) and at discharge (r = 0.4; p = 
0.003); and between CRP and TNF-α levels measured 
on admission (r = 0.3; p = 0.024) and at discharge (r 
= 0.4; p = 0.009).
No signiﬁ  cant correlations between CRP and factor 
VIIIc were found at any time during follow-up.
Clinical events and inflammatory marker levels 
during a one-year follow-up- At the end of a follow-up 
period of one year, there were 45 cardiovascular events 
(32 recurrent cases of angina without hospitalization, 
four deaths, eight readmissions for angina, and one 
non-fatal AMI). Of the inﬂ  ammatory markers analyzed, 
only IL-6 levels on admission correlated signiﬁ  cantly and 
independently with the composite endpoint, as shown in 
Tables 2 and 3.
DISCUSSION
CRP - This study showed that CRP levels were high 
in patients with unstable angina or non-ST-segment 
elevation AMI. Liuzzo et al.20 demonstrated that 65% 
of the patients had CRP levels ≥ 3 mg/L on admission, 
similar therefore to our ﬁ   ndings, in which 62.5% of 
the patients had CRP levels ≥ 4 mg/L (median CRP for 
controls) at the time of admission. On the other hand, 
elevated CRP plasma levels on admission were found 
in 65% of the patients, higher than those described by 
Biasucci et al21 (49%), which may suggest a higher risk 
population in the present study.
Following hospital discharge, O’Malley et al22 did not 
ﬁ  nd signiﬁ  cant differences in the CRP levels of patients 
and controls after three months of follow-up, which is 
similar to our ﬁ  ndings. To our knowledge, no comparative 
data is available in the literature that analyzes CRP levels 
after three months of follow-up in patients with non-ST-
segment elevation ACS.
Different studies have emphasized the usefulness of 
CRP measurement during acute coronary syndrome as a 
marker for future cardiac events12,20,23,24. However, this 
correlation has not been found by others22,25-28, which is 
again similar to our results.
IL-6 - Biasucci et al6 measured IL-6 levels in 38 
patients with unstable angina and in 29 with stable 
angina. Median IL-6 levels were 5.25 pg/mL in patients 
with unstable angina and below the detection limit (< 
3 pg/mL) in patients with stable angina. Likewise and 
using the same methodology, we found median IL-6 
levels of 6.15 pg/mL on admission in the case group 
with non-ST-segment elevation; in the control group, 
consisting of healthy subjects, median levels were 
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Table 1 – Characteristics of the Study Population
Cases Controls p value
Number of patients 40 40
Age (years, mean ± SD) 61 ± 12 65 ± 10 0.11
Gender (M/F) 22/18 22/18  1.0
Risk factors; number of patients (%):
-Family history of CAD 18 (45) 0 <0.001
-Dyslipidemia 14 (35) 9 (22.5) 0.069
-Diabetes 10 (25) 3 (7.5) 0.033
-Hypertension 38 (95) 14 (35) <0.001
-Cigarette smoking 14 (35) 2 (5) <0.001
Past history; number of patients (%):
-Previous MI > six months 11 (27.5) 0
-Stable angina 2 (5) 0
-Unstable angina 2 (5) 0
-CABG > six months 10 (25) 0
-PTCA > six months  4 (10) 0
Previous medication (%):
-Beta-blocker 14 (35) 1 (2.5) <0.001
-ACEI 15 (37.5) 4 (10) 0.007
-ASA 16 (40) 1 (2.5) <0.001
-Calcium antagonist 11 (27.5) 1 (2.5) 0.003
-Vastatin  6 (15) 1 (2.5) 0.108
-Digitalis 5 (12.5) 0 0.054
-Diuretics 12 (30) 7 (17.5) 0.293
-Nitrate 6 (15) 0 0.025
In-hospital medication (%):
-Beta-blocker 39 (97.5) 0
-ACEI 39 (97.5) 0
-ASA 40 (100) 0
-Calcium antagonist 22 (55) 0
-Vastatin 19 (47.5) 0
-Diuretics 16 (40) 0
-Nitrate 29 (72.5) 0
Admission diagnosis (%):
-Unstable angina 34 (85) 0
-Non-ST-segment elevation AMI 6 (15) 0
CAD - coronary artery disease; AMI - acute myocardial infarction; MR - myocardial revascularization; PTCA - percutaneous transluminal 
coronary angioplasty; ACEI - angiotensin-converting enzyme inhibitor; ASA - aspirin; ST - standard deviation; n - number; CABG - coronary 
artery bypass graft.
Fig. 1 – Median (25th-75th percentile) CRP levels (mg/L) of the case group compared with the control group at the four time points analyzed during 
follow-up.
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Fig. 2 – Median (25th-75th percentile) IL-6 levels (pg/mL) of the case group compared with the control group at the four time points analyzed during 
follow-up.
Fig. 3 – Median (25th-75th percentile) TNF-α levels (pg/mL) of the case group compared with the control group at the four time points analyzed during 
follow-up.
also below detection limit. These ﬁ  ndings support the 
hypothesis that detectable levels of IL-6 are related to 
atherosclerotic plaque instability, suggesting that this 
is not independent of myocardial necrosis, since this 
cytokine is also detectable in the absence of raised levels 
of creatine kinase or troponin T6. 
That study6 found a signiﬁ  cant correlation between IL-6 
and CRP levels (p = 0.013) measured on admission. In 
the present study, a signiﬁ  cant correlation between both 
markers was obtained not only on admission (p = 0.001) 
but also at discharge and at three months of follow-up. 
These ﬁ  ndings corroborate the hypothesis that, in the 
presence of ACS, increased levels of acute-phase proteins 
are a result of cytokine inﬂ  ammatory pathways.
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Fig. 4 – Mean ± SD ﬁ  brinogen levels (mg/dL) of the case group 
compared with the control group at the four time points analyzed 
during follow-up.
Fig. 5 – mean ± sd factor VIII levels (%) of the case group compared 
with the control group at the four time points analyzed during 
follow-up.Arquivos Brasileiros de Cardiologia - Volume 87, Nº 1, July 2006
With regard to IL-6 evolution after discharge, O’Malley 
et al22 found that, compared to controls, unstable patients 
showed signiﬁ   cantly higher IL-6 levels on admission, 
followed by a drop in three months, at which time IL-
6 levels in both groups became similar. In our study, 
although the number of patients with elevated IL-6 
levels in the case group decreased signiﬁ  cantly between 
discharge and at three months, this number remained 
signiﬁ  cantly higher than that of the control group in up 
to six months of follow-up. These differences may be 
explained by the fact that, in the O’Malley and et al study, 
the unstable angina population was at lower risk if we 
take into account that median IL-6 level on admission 
(3±3 pg/ml-1) was half of that obtained on admission in 
our study. It could be also speculated that the persistently 
elevated levels observed in our patients may be related 
to reactivation of the inﬂ  ammatory process.
As for the prognosis, it was recently demonstrated 
that high IL-6 levels on admission in patients with 
non-ST-segment elevation ACS is a good marker of 
future events7,29,30. Accordingly, in the present study 
no signiﬁ   cant and independent correlation was found 
between IL-6 levels on admission and cardiovascular 
events up to one year of follow-up.
TNF-α - Little data is available regarding TNF-α levels 
in non-ST-segment elevation ACS. Simon et al31 compared 
patients with unstable angina with healthy subjects and 
found no signiﬁ   cant difference between both groups. 
Similarly, in the present study TNF-α levels in the case 
group were not signiﬁ  cantly different from those of the 
control group in any of the periods studied. This might be 
justiﬁ  ed by Bazaran et al ﬁ  ndings that demonstrated that 
Table 2 – Inﬂ  ammatory Markers (admission) Correlation with Events* in a One-year Follow-up – 
Univariate Analysis
Inﬂ  ammatory marker with event
(n=25)
without event
(n=55) p-value 95% CI
CRP (median, 25th-75th percentile) 7.82, 1.73-12.21 4.74, 1.71-7.84 0.288 –1.21-5.26
IL-6 (median, 25th-75th percentile) 5.87, 2.37-13.90 1.32, 0-4.55 < 0.001 1.8- 5.87
TNF-α (median, 25th-75th percentile) 0, 0-1.24 0, 0-0 0.644 0-0
Fibrinogen (mean + SD) 272.1+ 67.9 288.6 + 73.1 0.337 –50.6-17.5 
Factor VIII (mean + SD) 73.8 + 42.8 66.9 + 23.7 0.354 –7.9-21.7
*Events = recurrent angina, readmission, myocardial infarction, death; CRP = C-reactive protein; IL-6 = interleukin-6;
TNF = tumor necrosis factor.
Table 3 – Inﬂ  ammatory Markers (admission) 
Correlation with Events* in a One-year Follow-up 
– Multivariate Analysis
Inﬂ  ammatory marker OR p value 
CRP -0.570 0.569
IL-6 2.190 0.029
TNF-α -0.757 0.449
Fibrinogen -1.431 0.152
Factor VIII-c 0.520 0.603
*Events = recurrent angina, readmission, myocardial infarction, 
death; CRP = C-reactive protein; IL-6 = interleukin-6; TNF = tumor 
necrosis factor.
plasma TNF-α levels in patients with AMI and unstable 
angina peaked within six hours and disappeared after 
24 hours from symptoms onset. In our analysis, TNF-
α levels on admission were higher compared with the 
control group, although not signiﬁ  cantly. Indeed, TNF-α 
plasma half-life is short, and baseline levels are low in 
most patients32.
Just as TNF-α levels did not rise signiﬁ  cantly compared 
with the control group at any time point of follow-up, 
neither was a correlation found between TNF-α levels 
and future events by the present study. Cusack et al30 also 
found no difference regarding inﬂ  ammatory marker levels 
among patients with unstable angina who subsequently 
experienced a major coronary event .
On the other hand, Ridker et al33, analyzing a sample 
of patients included in the CARE trial (Cholesterol And 
Recurrent Events), demonstrated that plasma TNF-α 
levels were elevated several months after AMI among 
subjects at high risk for recurrent coronary events. Blood 
samples were collected on an average of nine months after 
AMI, suggesting that the higher risk for recurrent coronary 
events associated with TNF-α is not merely the result of 
a transient marker increase following coronary occlusion. 
These ﬁ  ndings also suggest that subclinical persistent 
instability can be detected by presence of inﬂ  ammatory 
markers, such as TNF-α. Nevertheless, it is worth noting 
that the origin of persistently elevated TNF-α levels among 
high risk subjects (post-AMI) remains unknown33. 
Fibrinogen - Becker et al34 demonstrated an initial 
drop in ﬁ  brinogen levels within the ﬁ  rst 12 to 24 hours, 
exceeding baseline levels in 96 hours. This result is 
consistent with ﬁ  brinogen levels measured on admission 
in the present study, when lower levels were found, 
compared to those of the control group, which increased 
up to discharge. In sum, ﬁ   brinogen levels during the 
acute phase seem to peak between three to ﬁ  ve days, 
returning gradually to baseline values after resolution of 
the inﬂ  ammation35.
In the present study, ﬁ  brinogen levels in the case group 
were not signiﬁ  cantly different from those of the control 
group during hospitalization or at three months of follow-
up; however, at six months of follow-up, mean ﬁ  brinogen 
level was signiﬁ   cantly lower in case subjects than in 
control subjects, suggesting a negative rebound effect, 
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which may be related to an exacerbation of ﬁ  brinogen 
uptake after the acute episode. To our knowledge, that is 
no study that analyzes ﬁ  brinogen proﬁ  le up to six months 
of follow-up.
With regard to the prognostic value of ﬁ  brinogen levels 
after an acute coronary event, some authors describe 
this inﬂ  ammatory marker as useful10-14,34, while others 
do not36-38, as is the case of this study.
Factor VIII-c - Olinic et al17 found factor VIIIc activity 
to be signiﬁ  cantly higher (p < 0.01) in 17 patients with 
unstable angina than in 10 healthy control subjects. In 
our analysis, factor VIIIc activity in the case group was 
similar to that of the control group on admission and 
signiﬁ   cantly higher at discharge, returning to normal 
levels at three months of follow-up. Similarly, al-Nozha 
et al16 demonstrated progressive and signiﬁ  cant elevation 
in factor VIIIc activity in patients with unstable angina 
between eight hours and ﬁ  ve days of evolution. 
In the present analysis, no correlation was found 
between factor VIIIc and future events in ACS. In fact, 
there is no evidence in the literature regarding the 
prognostic value of increased factor VIIIc in ACS.
Study limitations - Firstly, the lack of correlation 
between the inﬂ  ammatory markers analyzed and future 
events, with the exception of IL-6, should be interpreted 
cautiously, due to the small number of patients studied. 
Furthermore, in this study, patients who underwent 
revascularization procedures at any time during the 
follow-up period were excluded so that the natural 
course of inﬂ  ammation could be documented in non-ST-
segment elevation ACS. In most studies, such patients 
are included in this population, which might affect the 
results. Secondly, routine laboratory measurements of 
inﬂ   ammatory markers, especially cytokines, present a 
host of technical difﬁ   culties, partly due to their short 
plasma half-lives and the presence of blocking factors39, 
resulting in differences when comparing several studies. 
Additionally, thus far no standard and widely used 
methodology is available, and there are several kits to 
measure a single product, such as high-sensitivity CRP . 
The relevance of this issue was underscored by Roberts 
et al40, who analyzed four high-sensitivity CRP methods 
and demonstrated differences among then in assessing a 
healthy population. Finally, troponin T was not measured 
in these patients, because this inﬂ  ammatory marker was 
not available at the time the study was made.
CONCLUSION
Indirect temporal analysis of plaque stabilization 
following acute coronary event varies according to the 
inﬂ  ammatory markers analyzed:
1. When taking CRP and factor VIII into account, 
plaque stabilization is suggested in up to three months. 
2. IL-6 analysis suggests stabilization as from the third 
month of follow-up, remaining at these levels, though 
elevated compared to controls in up to six months of 
follow-up.
3. Fibrinogen and TNF-α were not useful markers 
in evaluation of plaque stabilization, since they did not 
increase signiﬁ  cantly compared with the control group.
As for the prognosis, among the inflammatory 
markers analyzed, only IL-6 correlated significantly 
and independently with the development of future 
cardiovascular events.
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